版本:
中国

BRIEF-Can-Fite's liver drug enters mid-stage studies

May 3 Can Fite Biopharma Ltd

* Can-Fite's liver protective drug namodenoson enters phase II trial for treatment of nafld/nash Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐